The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...

Q3 2025 Earnings Call Transcript November 12, 2025 Autolus Therapeutics plc misses on earnings expectations. Reported EPS is ...

CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "recent successful capital raise." He emphasized the advancement of two clinical ...

The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.

Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scienti ...

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

The FDA has granted approval to the menin inhibitor ziftomenib (Komzifti) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations with no ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

This article deconstructs the IIH guidelines, contrasting medical management (acetazolamide, topiramate) with the practical ...